Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors

Inclusion Criteria: * Cancer survivors aged 19 years or older. * Peripheral, symmetrical pain in both feet occurring within 12 weeks of initiating chemotherapy with taxane or platinum agents (or their combination). * Patients experiencing at least grade 2 peripheral neuropathy as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, with an average pain intensity of 4 or higher on the Numerical Rating Scale (NRS) during the past week, following the completion of chemotherapy. * Concurrent use of selected analgesics (acetaminophen, nonsteroidal anti-inflammatory drugs \[NSAIDs\]) is permitted if the following conditions are met: 1. No new analgesics are introduced. 2. Current analgesics are not discontinued. 3. The total weekly 24-hour dose of analgesics does not vary by more than 10% during the 2 weeks prior to enrollment. * Ongoing treatment for peripheral neuropathy or neuropathic pain must be discontinued at least 7 days before randomization Exclusion Criteria: * Patients with a prior diagnosis of peripheral neuropathy due to diabetes, trauma, alcohol abuse, compression, or other causes, or those with a previously diagnosed central nervous system disorder. (Patients with pre-existing diabetes or thyroid disease who had no symptoms of peripheral neuropathy, such as numbness or tingling in the hands or feet, before chemotherapy may be included.) * Patients with significant psychiatric disorders, such as severe depression, bipolar disorder, or suicidal ideation. * Pregnant or breastfeeding patients. * Patients with a history of prior treatment with other neurotoxic chemotherapeutic agents. * Patients with renal impairment (creatinine clearance \< 30 mL/min) or hepatic dysfunction. * Patients with planned surgical procedures within 4 weeks of enrollment.